Egashira et al 2016 Retrospective CS Patients who underwent high-energy MTA of one or more Intervention: CT-guided 1. Adverse events: defined based on the Society of pulmonary tumours of primary or secondary origin MTA Interventional Radiology (SIR) classification of adverse United Kingdom Level IV events N = 44 (87) Anaesthesia: NR Risk of bias: High Tumour size median (range): 12 (6–45) Duration: median (range) Hospital setting 2 (1–9) minutes M/F ratio: 21:23 15 (6.2–29.5) months Comparator: N/A Median age (range): 66(17–89) years Primary tumour: 23/44 (52.2%) sarcoma, 16/44 (36.4%) colorectal, 2/44 (4.5%) lung, 1/44 (2.3%) oesophagus, 1/44 (2.3%) breast, 1/44 (2.3%) bladder. He et al (2006) Retrospective CS Patients with primary or secondary lung cancer who Intervention: US-guided 1. Adverse events: non-specified underwent MTA at a single centre MTA China Level IV N = 12 (16) Local anaesthesia Risk of bias: High Tumour size range: 20–60 mm Duration: NR Hospital setting M/F ratio: 7:5 Comparator: N/A Mean: 20 (6–40) months Mean age (range): 47.5 (31–69) years Reasons for choosing MTA included refusal of surgery (5), poor cardiopulmonary reserve (3), severe side effects from prior chemotherapy and/or radiotherapy (4)
Egashira et al 2016 United Kingdom Retrospective CS Level IV Risk of bias: High Hospital setting 15 (6.2–29.5) months Patients who underwent high-energy MTA of one or more pulmonary tumours of primary or secondary origin N = 44 (87) Tumour size median (range): 12 (6–45) M/F ratio: 21:23 Median age (range): 66(17–89) years Primary tumour: 23/44 (52.2%) sarcoma, 16/44 (36.4%) colorectal, 2/44 (4.5%) lung, 1/44 (2.3%) oesophagus, 1/44 (2.3%) breast, 1/44 (2.3%) bladder. Intervention: CT-guided MTA Anaesthesia: NR Duration: median (range) 2 (1–9) minutes Comparator: N/A 1. Adverse events: defined based on the Society of Interventional Radiology (SIR) classification of adverse events He et al (2006) China Retrospective CS Level IV Risk of bias: High Hospital setting Mean: 20 (6–40) months Patients with primary or secondary lung cancer who underwent MTA at a single centre N = 12 (16) Tumour size range: 20–60 mm M/F ratio: 7:5 Mean age (range): 47.5 (31–69) years Reasons for choosing MTA included refusal of surgery (5), poor cardiopulmonary reserve (3), severe side effects from prior chemotherapy and/or radiotherapy (4) Intervention: US-guided MTA Local anaesthesia Duration: NR Comparator: N/A 1. Adverse events: non-specified
1403%20-%20Final%20Contracted%20Assessment%20Report%20(ACCESSIBLE).docx